Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.5 CAD | -4.11% | -7.89% | +26.35% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 54% by 2026.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+31.77% | 1.02B | D- | ||
+42.07% | 6.23B | B- | ||
+5.38% | 3.32B | C | ||
-16.98% | 2.91B | B- | ||
-5.82% | 2.42B | - | D+ | |
+45.47% | 1.94B | - | ||
-12.67% | 1.59B | - | - | |
-3.91% | 1.58B | - | - | |
+44.56% | 1.49B | - | ||
-15.57% | 1.48B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CRON Stock
- Ratings Cronos Group Inc.